The authors aimed to determine the effect of radiation and surgery on urinary adverse effects in prostate cancer.

The authors aimed to determine erectile dysfunction and incontinence issues in patients following prostate surgery.

This study compared the effectiveness and safety of teneligliptin (Tenelia) to placebo in patients with type 2 diabetes (T2D) that was inadequately controlled with triple oral antidiabetic drugs (OADs). The study showed that teneligliptin may be considered as a fourth add-on OAD treatment in these patients.

This study aimed to determine which patients  benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination. 

The authors aimed to determine the benefit of sequencing docetaxel (Taxotere) and abiraterone (Zytiga) treatment to improve progression-free survival (patients who did not experience cancer growth after treatment) in patients with metastaic (cancer that has spread) hormone-resistant (cancer that does not respond to hormone treatment) prostate cancer.

The authors concluded that there was no evident benefit of alternative sequencing in patients with metastatic hormone-resistant prostate cancer.

This study aimed to investigate treatments given after chemotherapy and hormonal therapy for metastatic prostate cancer, resistant to castration. This study found some benefit in abiraterone (Zytiga) or enzalutamide (Xtandi) but not in using docetaxel (Taxotere) again.

The authors evaluated whether robot-assisted surgery, in patients with high-risk prostate cancer, compares well to other surgical technique.

This article investigated complications other than urinary incontinence or erectile dysfunction associated with radiotherapy and radical prostatectomy treatments for prostate cancer.

This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic.

This study evaluated the effectiveness and safety of opicapone (Ongentys) for the treatment of non-motor symptoms in patients with Parkinson's disease (PD). The data showed that opicapone improved the non-motor symptoms and quality of life (QoL) with manageable side effects in patients with PD.